back to press releases

Quanterix Expanding Transformative Biomarker Technology Portfolio Into Oncology

Launching Test Bed for up to 10-plex assays with Simoa Sensitivity and Specificity to Advance Cancer Research

Lexington, Mass. – Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced an Early Access Program for the latest advance in Simoa Sensitivity assays for oncology. The Early Access test bed will make available a new 10-plex assay for oncology research and drug development along with a benchtop imager called SP-X™ Imaging and Analysis System. The SP-X™ Imager and 10-plex assay panel utilizes a proprietary planar array technology that has been under development for the past several years to address the needs of onocology researchers, particularly the rapidly expanding fields of immuno-oncology and immunotherapy. The SP-X™ system is a complete benchtop system that offers advanced multiplexing capabilities with Simoa Sensitivity – at levels so low the assays can measure concentrations of key circulating cytokines and immunological biomarkers across all stages of disease progression including normal healthy baseline levels.

“The SP-X and accompanying large planar array menu of multiplex panels represent the latest evolution of the industry leading Simoa technology and marks our continued commitment to driving today’s healthcare revolution into oncology,” said Kevin Hrusovsky, Chief Executive Officer, President, and Chairman of Quanterix. “Our Simoa technology has already led to major scientific breakthroughs with 300 third-party peer-reviewed publications, primarily in CNS and neurodegenerative diseases. Our new SP-X platform enables us to expand our Simoa franchise into oncology and immuno-oncology research, which we estimate to be 3 to 5 times the size of our current neurology markets.”

With the same unprecedented sensitivity and precision of current Simoa systems, the SP-X™ offers exceptional multiplexing biomarker detection capabilities in a compact size. For the first time, researchers are able to access over one thousand assay configurations for oncology up to 10-plex without sacrificing sensitivity on an easy-to-use, incredibly robust instrument. The assay broad menu covers more than 50 analytes and offers researchers the ability to easily develop custom homebrew assays, further extending the range of applications to include PK/PD and immunogenicity assays. The chemiluminescent SP-X™ platform was designed to transform oncology and immuno-oncology research, where the ability to measure multiple analytes simultaneously is critical but has not been possible with sufficient sensitivity until now. With the SP-X™, researchers in these areas will be able to more quickly see the effects of certain drugs on individual cancer patients even at the earliest stages of the disease.

“Cancer is one of the leading causes of death, with more than 1.7 million new cases expected to be diagnosed in the U.S. alone this year. Creating safe and effective drugs to combat the disease has posed challenges for drug developers, and this new platform represents the product of a major investment on our part to address an important unmet need in oncology research,” continued Hrusovsky.

The SP-X™ also offers state-of-the-art imaging and data analysis, complete with proprietary acquisition and machine learning algorithms, and streamlined semi-automated sample preparation workflows. The compact benchtop instrument comes complete with an intuitive touch-screen interface and onboard high-resolution camera, requiring minimal maintenance and calibration.  

The new SP-X™ will be on display today for the first time at the Society for Immunotherapy of Cancer Conference in Washington, D.C. For more information on the SP-X™ and to see the technology in action, please visit;

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.


Lindsay Poole
PAN Communications